Date: 2015-12-10
Type of information: Distribution agreement
Compound: cord blood processing technologies
Company: Biosafe (Switzerland) StemLife Bhd(Malaysia)
Therapeutic area: Technology - Services
Type agreement: distribution supply
Action mechanism:
Disease:
Details: * On December 10, 2015, Biosafe and StemLife announced that they have signed a long-term supply agreement in respect of StemLife’s cord blood banking activities in Malaysia. Effective immediately, Biosafe is supplying its fully automated Sepax® cell processor and associated single use kits to StemLife, which will use Biosafe technology for all its cord blood processing requirements.
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors.
Financial terms:
Latest news:
